secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2026-08-10T21:14:42+00:00
Accession:  0001193125-26-342669
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Erasca appoints Charles Fuchs as President, R&D; adopts 2026 inducement plan
----------------------------------------------------------------------------

- Charles S. Fuchs, M.D., M.P.H., appointed President, R&D effective Aug 10, 2026.
- Prior roles: CMO at Tubulis (acquired by Gilead), SVP Global Head Oncology at Genentech/Roche, Yale Cancer Center director.
- Compensation: $570k base, 45% target bonus, stock options for 1.3M shares vesting over 4 years.
- Inducement Plan adopted, reserving 6.2M shares for equity awards without stockholder approval.
- Options: 1,278,520 under new Inducement Plan, remainder under 2021 Incentive Plan; exercise price at close on grant date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526342669/0001193125-26-342669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526342669/eras-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer